CDRH: Microbiology Devices Panel of the Medical Devices Advisory Committee (MDAC)
20 November 2026
Contents updated on 19 Nov 2026
Legend
Transcript markers
- text Sentence being played
- text Search result
- text Intervention cited by the link you opened
Click a sentence to play the video from that moment. Select text to quote it with the speaker, timestamp and link.
More options
U.S. Food and Drug Administration FDA Advisory Committees
04:28 - 05:31
Speaker 4
2026 meeting of the Microbiology Devices Panel of the Medical Devices Advisory Committee to order. I'm Dr. Robin Patel and I'll be the acting chairperson for today's meeting. I'm a medical microbiologist and an infectious diseases physician at the Mayo Clinic in Rochester, Minnesota, where I'm also professor of medicine and professor of microbiology, and I develop and oversee the operation of advanced diagnostics, including sequencing-based diagnostics in my clinical practice. Today, the panel will meet to discuss and make recommendations to the FDA on examining the scientific, clinical, and public health dimensions of the use of pathogen-agnostic sequencing as it relates to emergency preparedness and response efforts, and to support discussion of opportunities, implementation considerations, and potential priorities for future coordination. The preparedness use could cover local outbreaks, national outbreaks, known pathogens, or unknown pathogens.
05:31 - 07:30
Speaker 2
This meeting is being held to satisfy, in part, a requirement under the Food and Drug Omnibus Reform Act of 2022, FDORA. The FDA is seeking input on the design of these tests and how opportunities and challenges associated with their development, including how to establish an agile but effective and validated bioinformatic system that can account for frequent sequence changes, is needed. I will now read a statement regarding the Federal Advisory Panel Act and the Government in the Sunshine Act. The advisory panel topics, such as the one before us today, may bring a range of views, including views individuals may hold strongly. Our goal is to ensure the meeting provides a fair, orderly, and open forum for discussion, and views may be expressed without interruption.
Thus, a gentle reminder, individuals may speak on record when recognized by the chairperson, and we appreciate everyone's cooperation in helping us conduct a productive and respectful meeting. Consistent with the principles of the Federal Advisory Panel Act and the Government in the Sunshine Act, panel members should ensure discussions related to the meeting topic occur in the open session and as part of the public record. Members are therefore reminded not to discuss the meeting topic during the breaks, during lunch, or at other times outside of this open meeting session. Thank you for your cooperation. I will now ask the FDA participants as well as members of today's panel to introduce themselves, and we'll start over on my left with our FDA colleagues and then proceed around the table.
Please unmute your microphone, then state your name, your organization, expertise, or role, and then mute your microphone once again, and then we'll move on to the next person, and we'll begin with Afton Ross.
The rest of the transcript is for Pro customers
Unlock the full transcript, chat, and every analysis feature with Polyfact Pro.
The video itself stays free to watch, in full, no account needed.
Start a free trial